In stock COA-25%
In stock COA DOCUMENT SLOT-25%
Neuro ResearchPT-141
The active compound in Vyleesi®
Melanocortin MC3R/MC4R agonist studied for central nervous system melanocortin pathway research.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundPT-141
Presentation10mg vial
Also known asVyleesi®
CategoryNeuro Research
AvailabilityIn stock
Batch COACertificate supplied with order
You save €13.00 on this presentation — an extra 10% off when you pay with crypto.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II through removal of the C-terminal amide. It acts primarily on MC3R and MC4R receptors in the central nervous system. Unlike its parent compound MT2, PT-141 has minimal effects on melanogenesis via MC1R, making it a more selective tool for studying central melanocortin pathways. Under the brand name Vyleesi, bremelanotide received FDA approval in 2019, representing one of the few peptide drugs targeting CNS melanocortin receptors to reach clinical use.
Mechanism of Action
PT-141 activates MC3R and MC4R in the hypothalamus and limbic system. MC4R activation in the paraventricular nucleus triggers downstream signalling through oxytocin and dopaminergic pathways, while MC3R modulation in the ventral tegmental area influences reward circuitry. The compound acts through Gs-coupled cAMP elevation and Gq-coupled calcium signalling, depending on the receptor subtype and cellular context. Its central mechanism of action, distinct from peripheral vasodilatory pathways, makes it a unique pharmacological tool for studying the intersection of melanocortin signalling and behavioural neuroscience.
Research Applications
- Central melanocortin receptor (MC3R/MC4R) research
- Hypothalamic neuropeptide pathway investigation
- Oxytocin and dopaminergic circuit interaction studies
- Behavioural neuroscience and reward pathway research
- Melanocortin structure-activity relationship studies
FREE TOOL
Reconstitution calculator
Enter your reconstitution to get the draw volume for PT-141.
Concentration5.00 mg/ml
Draw volume0.050 ml
On the syringe5.0 units
Doses per vial40
5units
Pull the plunger to 5.0 units on a 1 ml U‑100 syringe0.050 ml · 5.00 mg/ml · 40 doses per vial
Concentration = peptide mass ÷ water volume. Unit readings assume U-100 insulin syringes, graduated 100 units per millilitre. For laboratory calculation only — not dosing guidance.